Introduction
Despite a growing population of endometrial cancer survivors, to date research has focused on advancements in surgical approaches and the introduction of new therapies. To improve the lives of this increasing population, there is a clear need to improve understanding of the breadth of survivorship concerns.
Aim
The overall aim of this 3-step project, driven by the objectives of the ANZGOG EDEN Initiative Survivorship Focus Group, is to develop a list of the contemporary survivorship issues for women with endometrial cancer that can be used to guide future research and the provision of supportive care. This abstract describes step 1) synthesising the current evidence by conducting an umbrella review, and step 2) identifying additional contemporary outcomes not identified in the review via a healthcare professional (HCP) survey.
Methods
A search of Medline was performed to identify reviews published between 2013-2023 that reported survivorship outcomes in endometrial cancer survivors. Articles were screened by two authors and data extracted on reported survivorship outcomes, review characteristics, and quality of studies. Subsequently, HCPs completed a survey rating the importance of the survivorship issues identified in the umbrella review and listing additional outcomes not previously identified.
Results
From 42 reviews deemed eligible (out of 201 reviews identified as potentially relevant), 25 survivorship issues were identified. There was extensive heterogeneity in study characteristics between and within reviews and primary studies included in the reviews were mostly described as being of low quality. HCPs (n=37) identified 28 additional survivorship issues, with two new broad categories: surveillance and recurrence, and return to usual activities.
Conclusion
The next step in meeting EDEN-ANZGOG identified research goal is to use the combined findings of the review and HCP survey to develop a patient survey to explore the most frequent and burdensome survivorship issues experienced after endometrial cancer diagnosis.